Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Proper Nutrition for Older Adults and Residents With Alzheimer’s

Proper Nutrition Can Be a Challenge Even for those who are young and healthy, it can be a challenge to incorporate the nutrients essential to healthy living into our daily diets. But for those living in nursing homes or in assisted living residences, undernutrition from undereating can be a real danger. For caregivers and staff…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

Proper Nutrition Can Be a Challenge

Even for those who are young and healthy, it can be a challenge to incorporate the nutrients essential to healthy living into our daily diets. But for those living in nursing homes or in assisted living residences, undernutrition from undereating can be a real danger. For caregivers and staff of long-term care facilities, knowing the reasons behind an apparent lack of appetite in their residents and possible solutions, can go a long way in ensuring that daily nutritional needs are met.

Nutrition Is Not Always Easy

For many elderly patients, treatments for health issues may be limiting their appetite. Many medications have appetite suppressing side effects, and treatments that result in nausea can also limit the amount of food a resident can consume.1 The disorders themselves can hinder eating as well. Neurological diseases may make it challenging to control the muscles needed for oral food consumption, sometimes making it painful to eat.2

While some of these issues require individualized care, there are practices that LTC facilities can put in place to encourage increased appetites among their patients. Using larger plates, for instance, tricks the mind into believing that the portion served is smaller than its actual size. Additionally, by encouraging socialization during meals, moods are lifted, and appetites may return. Cooking staff can also add variety into the tastes and flavors of meals served, which can often be enough to increase the desire to eat.

Changing How We Look at Food

Residents with Alzheimer’s pose new challenges when it comes to eating. Not only do many of the already mentioned impediments exist, but there is also a cognitive dissonance between what is served and what the patient sees. It’s all well and good to serve a balanced diet, but if a patient can’t distinguish the food from the plate it sits on, not much will be eaten. Seeking a solution, scientists at Boston University found that Alzheimer’s patients who were served meals on red plates ate 25% more than those served the same meal on white plates.3 The researchers found that presenting food on a high contrast background, like a bold colored plate, could mitigate the loss of visual perception the patient was experiencing.4

Red Plates: Designed with Elderly Patient’s in Mind

At AliMed, we take these same principles and apply it to our assistive dining aids. Our red dinnerware sets provide a high-contrast background to food, making it easier for patients with declining vision to see what’s on the plate and is less likely to show stains. Our brightly colored plates are also likely to increase food intake for people with Alzheimer’s 5.

REFERENCES

  1. https://healdove.com/older-adults/Elderly-Nutrition
  2. https://www.nidcd.nih.gov/health/dysphagia
  3. http://www.homesweethomecareinc.com/caregiver-helpers/red-plates-for-dementia
  4. http://www.alzheimersweekly.com/2014/08/red-plates-for-eating-with-dementia.html
  5. http://www.alzheimersweekly.com/2014/08/red-plates-for-eating-with-dementia.html

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512